

**Minutes of the Lancashire Medicines Management Group Meeting  
Held on Thursday 12<sup>th</sup> September 2013 at Preston Business Centre**

**PRESENT:**

Dr Tony Naughton (TN)	Chair	Lancashire CCG Network
Louise Winstanley (LW)	CCG Lead Pharmacist	NHS Fylde and Wyre CCG
Melanie Preston (MP)	Assistant Director Medicines Optimisation	NHS Blackpool CCG
Dr Pervez Muzzafar (PM)	GP Prescribing Lead	NHS Blackburn w/ Darwen CCG
Dr Kamlesh Sidhu (KS)	GP Prescribing Lead	NHS Lancashire North CCG
Gareth Price (GP)	Chief Pharmacist	Lancashire Teaching Hospitals NHS Foundation Trust
Alastair Gibson (AG)	Chief Pharmacist	Blackpool Teaching Hospitals
Lisa Rogan (LR)	Head of Medicines Commissioning	East Lancs & BwD CCGs
David Shakespeare (DS)	Drugs & Therapeutics Committee Chair	Lancashire Teaching Hospitals Foundation Trust
Julie Landale (JLan)	Head of Medicines Optimisation	NHS Chorley & South Ribble and Greater Preston CCGs
Pauline Bourne (PB)	Senior Pharmacist	University Hospitals of Morecambe Bay
Dr Sigrun Baier (SB)	GP Director	Chorley and South Ribble CCG
Christine Woffindin (CW)	Pharmacist	East Lancashire Hospital Trust
Dr S Karunanithi (SK)		Public Health Lancashire
Catherine Fewster	Chief Pharmacist	Lancashire Care NHS Foundation Trust

**IN ATTENDANCE:**

Elaine Johnstone (EJ)	Senior Executive – Medicines Management	NHS Staffordshire and Lancashire CSU
Brent Horrell (BH)	Head of Medicines Commissioning	NHS Staffordshire and Lancashire CSU
Julie Lonsdale (JLon)	Head of Medicines Performance	NHS Staffordshire and Lancashire CSU
Warren Linley (WL)	Senior Medicines Commissioning Pharmacist	NHS Staffordshire and Lancashire CSU
Nicola Schaffel	Medicines Optimisation Lead Pharmacist	NHS Chorley & South Ribble and Greater Preston CCGs
Dr Lizzie MacPhie (LM)	Consultant Rheumatologist	Lancashire Care NHS Foundation Trust
Dr Ayesha Madan (AM)	Consultant Rheumatologist	Lancashire Care NHS Foundation Trust

ITEM	SUMMARY OF DISCUSSION	ACTION
2013/110	<p><b>WELCOME &amp; APOLOGIES FOR ABSENCE</b></p> <p>The Chair welcomed everyone to the meeting and introduced Sigrun Baier who has joined the group as the GP representative from Chorley &amp; South Ribble CCG. Nicola Schaffel (attending as an observer) was also introduced.</p> <p>Apologies for absence were noted on behalf of Dr Tom Marland, Mark Collins, Nicola Baxter, Linda Bracewell, George Nasmyth, Ann Bowman and Dr Li Kam Wa.</p>	

ITEM	SUMMARY OF DISCUSSION	ACTION
2013/111	<b>DECLARATIONS OF INTEREST PERTINENT TO AGENDA</b> None	
2013/112	<b>DECLARATION OF ANY OTHER URGENT BUSINESS</b> None	
2013/113	<b>MINUTES OF THE LAST MEETING – 11<sup>th</sup> July 2013</b> The minutes of the meeting held on 11 <sup>th</sup> July 2013 were agreed as an accurate record.	
2013/114	<b>MATTERS ARISING (not on the agenda)</b> None	
2013/125 (order change)	<p><b><u>Rheumatology Pathway</u></b> <b>(agenda item brought forward)</b></p> <p>LM gave a presentation explaining the Rheumatology Alliance proposed flexes on the use of anti-TNF<math>\alpha</math> and other biologics in the rheumatoid arthritis clinical pathway.</p> <p>There was a discussion around the consultation process and how non-responders were to be considered. Members were urged to send in an email even if they had no comments to make.</p> <p>WL talked through the proposed flexes, explaining the CSU review of the supporting evidence for each one. This was followed by general discussion which concluded that:</p> <p>LMMG recommends and supports flexes 1, 2c, 2d, 3, 4, 6 and 7 It was agreed by majority that flex 5 be taken out as the recommendation and support for flex 6 negated the need for flex 5. With regards to flex 2a (history of cancer within the last 5 years) and 2b (history of malignant melanoma) it was felt that more time was needed to consider the evidence and that these will be discussed at the next LMMG meeting. TN recommended that additional peripheral evidence, such as the Lancashire wide commissioning principles document, which included the ethical framework for decision-making, be circulated before the topic was discussed again by LMMG.</p> <p><b>Action:</b> <b>BH to circulate commissioning principles document to the group.</b></p> <p><b>LM to check what supporting information is available from the British haematology society and cancer registry in relation to flexes 2a and 2b.</b></p> <p>LM and AM left the meeting at this point</p>	<p><b>BH</b></p> <p><b>LM</b></p>
2013/115	<p><b><u>Medicines for Actinic Keratosis</u></b></p> <p>WL talked through the new medicines recommendation paper for the medicines reviewed for the treatment of actinic keratosis, which were: Fluorouracil + salicylic acid (Actikerall®), imiquimod (Zyclara®) and ingenol (Picato®▼)</p> <p>Following discussion LMMG recommended that only ingenol be supported for commissioning across Lancashire, with a recommended traffic light status of <u>AMBER 0</u>. <u>The other two products were not recommended and so have proposed traffic light status of black.</u></p> <ul style="list-style-type: none"> <li>• ingenol (Picato®▼) <u>RAG status AMBER 0</u></li> <li>• salicylic acid (Actikerall®) <u>RAG status BLACK</u></li> <li>• imiquimod (Zyclara®) <u>RAG status BLACK</u></li> </ul>	

ITEM	SUMMARY OF DISCUSSION	ACTION
2013/116	<p><b><u>Oxcarbazepine</u></b></p> <p>WL talked through the new medicines recommendation paper for Oxcarbazepine (Trileptal®) for the treatment of epilepsy</p> <p>Following discussion LMMG recommended:</p> <p>Option 2 Oxcarbazepine (Trileptal®) is recommended for use as monotherapy or adjunctive therapy in partial (focal) epilepsy only when carbamazepine, lamotrigine, sodium valproate and levetiracetam are not appropriate or not tolerated.</p> <p>RAG status AMBER 0</p>	
2013/117	<p><b><u>Tapentadol SR</u></b></p> <p>WL talked through the new medicines recommendation paper for Tapentadol SR (Palexia® SR) for severe chronic pain in adults.</p> <p>A discussion took place and the group decided to recommended option 1; not to recommend for use.in severe non-cancer pain.</p> <p><u>RAG status BLACK</u></p> <p>However, it was agreed that option 1 and option 2 could be reviewed pending guidelines in conjunction with pain management</p> <p><b><u>Action:</u></b>  <b>BH to contact pain management consultants to ask them to consider working with the CSU to develop a pain management pathway.</b></p>	BH
2013/118 119/120a	<p>Due to time constraints a decision was taken to defer the following agenda items to the next meeting</p> <p><u>118 LMMG – New medicines reviews work plan update</u></p> <p><u>119 Horizon Scanning quarter 3 2013-14</u></p> <p><u>120a 120b New NICE Technology Appraisal Guidance for Medicines July – August 2013</u></p>	
2013/122	<p><b><u>Shingles vaccine</u></b></p> <p>JLon presented this paper explaining that an amendment had been made to the National Immunisation Schedule, to include Shingles vaccine for people aged 70. As a result, LMMG needed to review the status of shingles vaccine in Lancashire.</p> <p>It was agreed to change the RAG status of shingles vaccine from BLACK to GREEN.</p>	
2013/123	<p>TN informed the LMMG that the CCG network was in the process of reviewing all of their collaborative commissioning arrangements, in particular considering the constraints associated with CCG status as separate statutory bodies. The intent behind the review is to find appropriate means to streamline collaborative decision-making across Lancashire. This review will have an impact on how the LMMG operates in future.</p> <p>TN will ensure that the LMMG members are regularly updated as the CCG network continue to progress this.</p>	TN

ITEM	SUMMARY OF DISCUSSION	ACTION
2013/124	<p><b><u>Vitamin D guidelines</u></b>            JLon talked through the progress of the guidelines            A comparison of the local Vitamin D guidelines with national guidelines had highlighted a few differences. The local guidelines have been amended to reflect the National Osteoporosis Society document as requested by LMMG. Products have been listed in the appendix, highlighting the options available which are suitable for vegetarians, allow for religious beliefs and those that are without allergenic risks.</p> <p><b><u>Action:</u></b>  <b>It was agreed that JLon upload the updated guidelines onto the LMMG website as an LMMG product</b></p>	JLon
2013/126	<p><b><u>Melatonin Prescribing</u></b>            DS gave a brief overview of melatonin prescribing in patients with paediatric neurologically mediated sleep disturbances</p> <p><b><u>Action:</u></b>  <b>LMMG agreed that a review of melatonin prescribing should be included on the LMMG work plan</b></p>	BH
2013/127	<p><b><u>Lancashire Care FT Drug &amp; Therapeutic Committee Minutes 23<sup>rd</sup> July 2013</u></b>            The minutes of the Lancashire Care Drugs &amp; Therapeutic Committee meeting held on 23<sup>rd</sup> July 2013 were received for information.</p>	

**Date and time of the next meeting**

Thursday 10th October 9.30 am to 11.30 am, Meeting Room 2, Preston Business Centre

**ACTION SHEET FROM THE  
LANCASHIRE MEDICINES MANAGEMENT GROUP THURSDAY  
12<sup>th</sup> September 2013**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2013/125</b>	<b><u>Rituximab</u></b>  BH to circulate the commissioning principles to the committee.  LM to check recommendations from the haematology society and cancer regulations.	<b>BH</b>  <b>LM</b>	<b>30.9.13</b>  <b>30.9.13</b>
<b>2013/118/119 120a/120b</b>	Following agenda items not discussed to be added to the agenda for October LMMG meeting <u>118 LMMG – New medicines reviews work plan update</u> <u>119 Horizon Scanning quarter 3 2013-14</u> <u>120a 120b New NICE Technology Appraisal Guidance for Medicines July – August 2013</u>	<b>EJ</b>	<b>LMMG Agenda 10.10.2013</b>
<b>2013/117</b>	<b><u>Tapentadol SR</u></b>  BH to contact pain management consultants to request them to develop a pain prescribing pathway	<b>BH</b>	<b>30.9.13</b>
<b>2013/124</b>	<b><u>Vitamin D guidelines</u></b>  JLon to upload the updated guidelines onto the LMMG website as an LMMG product	<b>JL</b>	<b>Update website 19.9.13</b>
<b>2013/126</b>	<b><u>Melatonin prescribing</u></b>  BH to include on the LMMG work plan	<b>BH</b>	<b>16.9.13</b>